What Hypertrophic Cardiomyopathy Management Actually Looks Like
When I sit across from a patient who has just been told they have hypertrophic cardiomyopathy, the first thing I see is fear. And that fear is understandable. HCM is the most common inherited cardiac condition, affecting roughly 1 in 500 people, and it carries associations with sudden cardiac death in young athletes that dominate headlines. But here is what I want every patient and family member to understand: for the vast majority of people with HCM, this is a manageable condition. The key word is manageable — not curable, but absolutely livable, with the right plan.
As an echocardiographer and nuclear cardiologist, I spend my days imaging the heart in extraordinary detail. I measure the thickness of the interventricular septum, assess the degree of left ventricular outflow tract obstruction, evaluate mitral valve function, and track how the heart muscle responds to treatment over time. Hypertrophic cardiomyopathy management is not a one-time event. It is an ongoing, individualized process that evolves as you do.
This article is meant to give you a clear picture of what that process involves — the medications, the monitoring, the lifestyle decisions, and the moments when a more aggressive intervention may be necessary.
Understanding Your HCM: Why Imaging Drives Every Decision
Not all HCM is the same. The treatment plan that works for one patient may be entirely wrong for another, and the reason comes down to anatomy and physiology — details we can only capture through advanced imaging.
Echocardiography is the cornerstone of HCM assessment. A comprehensive transthoracic echocardiogram tells us:
- Septal wall thickness: Normal is roughly 6-11 mm. In HCM, we commonly see measurements of 15 mm or greater, and in severe cases, 30 mm or more.
- Left ventricular outflow tract (LVOT) gradient: This is a pressure measurement that tells us whether the thickened septum is physically blocking blood flow out of the heart. A resting gradient above 30 mmHg is considered obstructive. Gradients above 50 mmHg typically warrant treatment.
- Mitral regurgitation: The thickened septum often pulls the mitral valve out of position, causing it to leak. This worsens symptoms and adds volume load to the heart.
- Diastolic function: Even when blood flows out normally, the stiffened muscle may not relax properly to fill with blood. This is a major driver of shortness of breath and fatigue.
Beyond standard echocardiography, I frequently use stress echocardiography to provoke gradients that are not present at rest. Some patients have minimal obstruction sitting quietly in my office but develop significant gradients of 70, 80, even 100 mmHg or more with exercise. This is called provocable obstruction, and it changes management entirely.
Cardiac MRI adds another layer, especially for assessing myocardial fibrosis using late gadolinium enhancement. According to ACC/AHA guidelines, the extent of fibrosis on MRI is an independent risk factor for sudden cardiac death and can influence decisions about implantable cardioverter-defibrillator (ICD) placement. If you have not had a cardiac MRI as part of your HCM evaluation, it is worth discussing with your team.
HCM Treatment: Medications, Procedures, and Newer Options
Medical Therapy: The Foundation of HCM Treatment
For most patients with symptomatic obstructive HCM, medication is the first line of treatment. The goal is to reduce the LVOT gradient, improve filling time, and control symptoms like exertional dyspnea, chest pain, and lightheadedness.
- Beta-blockers (such as metoprolol or atenolol) remain the first-line agents. They slow the heart rate, reduce contractility, and allow more time for the ventricle to fill. Many patients experience meaningful symptom improvement on beta-blockers alone.
- Non-dihydropyridine calcium channel blockers (verapamil is the most commonly used) serve as an alternative for patients who cannot tolerate beta-blockers.
- Disopyramide, a Type 1A antiarrhythmic, has a direct negative inotropic effect that can significantly reduce LVOT gradients. It is typically used in combination with a beta-blocker or calcium channel blocker because of its potential to accelerate AV node conduction.
- Mavacamten (Camzyos): This is a newer class of medication — a cardiac myosin inhibitor — approved by the FDA in 2022 for symptomatic obstructive HCM. Clinical trials (EXPLORER-HCM, VALOR-HCM) demonstrated substantial reductions in LVOT gradients and improvement in exercise capacity. Mavacamten has changed the conversation for many patients who previously would have been referred directly for surgery. However, it requires careful monitoring of ejection fraction, and not everyone is a candidate.
Septal Reduction Therapy: When Medications Are Not Enough
When medications fail to control symptoms or when LVOT gradients remain significantly elevated (typically above 50 mmHg at rest or with provocation), the next step is septal reduction therapy. There are two primary options:
- Septal myectomy: This is open-heart surgery in which a fellowship-trained cardiovascular surgeon removes a portion of the thickened septal muscle. At experienced centers, surgical myectomy has a success rate exceeding 95% in relieving obstruction, with operative mortality rates below 1% when performed by high-volume surgeons. It remains the gold standard for septal reduction, particularly in patients who also need mitral valve repair or other concomitant procedures.
- Alcohol septal ablation: This is a catheter-based approach in which a small amount of alcohol is injected into a septal perforator artery, creating a controlled infarction that thins the septum over time. It avoids open surgery but carries its own risks, including a higher rate of complete heart block requiring a permanent pacemaker (10-20% in many series) and less predictable gradient reduction compared to myectomy.
The choice between myectomy and ablation is highly individualized and depends on anatomy, age, comorbidities, and the expertise available at your center. This is precisely the kind of decision where a second opinion from an independent cardiac surgery team can provide clarity.
ICD Placement: Preventing Sudden Cardiac Death
Not every HCM patient needs a defibrillator, but risk stratification is a critical component of hypertrophic cardiomyopathy management. The ACC/AHA guidelines recommend evaluating five major risk factors:
- Family history of sudden cardiac death attributed to HCM
- Unexplained syncope
- Massive left ventricular hypertrophy (wall thickness 30 mm or greater)
- Non-sustained ventricular tachycardia on ambulatory monitoring
- Abnormal blood pressure response during exercise testing
Additional modifiers include the extent of late gadolinium enhancement on MRI, the presence of an apical aneurysm, and systolic dysfunction. The decision to implant an ICD should be made collaboratively, weighing the statistical risk against the lifelong commitment of device management. Use our free cardiac surgery risk calculator as a starting point for understanding your overall surgical risk profile.
HCM Lifestyle: What You Can and Cannot Control
This is where I see the most confusion and, frankly, the most unnecessary restriction. Let me be direct: a diagnosis of HCM does not mean you must live in a bubble.
Exercise and Physical Activity
The old recommendation — avoid all competitive sports and vigorous exercise — has been substantially nuanced in recent years. The 2020 ACC/AHA guidelines now support a shared decision-making approach, acknowledging that moderate-intensity exercise is generally safe and beneficial for most HCM patients. Studies, including data from the LIVE-HCM registry, have shown that many patients with HCM can participate in vigorous exercise without increased arrhythmic events, provided they have undergone appropriate risk stratification.
What I tell my patients:
- Avoid abrupt, maximal exertion — sprinting from a standstill, heavy competitive lifting — especially if you have significant obstruction.
- Regular, moderate aerobic exercise (walking, cycling, swimming at a comfortable pace) is generally encouraged.
- Stay hydrated. Dehydration reduces blood volume and worsens obstruction.
- Avoid exercising in extreme heat.
- If you are cleared for more vigorous activity, build up gradually and listen to your body. Symptoms like lightheadedness, palpitations, or unusual shortness of breath during exertion should prompt immediate evaluation.
Dietary and Daily Habits
- Hydration is critical. I cannot overemphasize this. Low blood volume increases the velocity of blood flow through an already narrowed outflow tract, worsening obstruction and symptoms.
- Alcohol in moderation. Alcohol is a vasodilator and can acutely worsen gradients. Binge drinking is particularly dangerous.
- Caffeine in moderate amounts (one to two cups of coffee) is generally fine for most patients, though individual tolerance varies.
- Avoid medications that worsen obstruction, including certain decongestants (pseudoephedrine), digoxin, and high-dose diuretics without medical supervision. Always check with your cardiologist before starting any new medication, including over-the-counter products.
Ongoing Monitoring: What Your Follow-Up Schedule Should Look Like
Hypertrophic cardiomyopathy management does not stop after the first echocardiogram. Guidelines recommend:
- Annual echocardiography for stable patients to track wall thickness, gradients, mitral regurgitation, and diastolic function.
- Periodic 48-hour Holter monitoring (typically every one to two years) to screen for non-sustained ventricular tachycardia, a key risk factor for sudden death.
- Repeat cardiac MRI every three to five years, or sooner if clinical status changes, to reassess fibrosis burden.
- Exercise stress testing every one to two years to evaluate functional capacity, blood pressure response, and provocable gradients.
- Genetic counseling and family screening: HCM is inherited in an autosomal dominant pattern. First-degree relatives should be screened, typically with an echocardiogram and ECG, beginning in adolescence and continuing through adulthood.
If your current follow-up plan does not include these elements, bring it up with your cardiologist. Gaps in monitoring are gaps in safety.
When to Get a Second Opinion on Your HCM Treatment Plan
In my practice, I encounter several situations where I strongly encourage patients to seek an independent review:
- You have been told you need septal myectomy or alcohol ablation, and you want to confirm the recommendation is appropriate for your anatomy.
- Your symptoms are worsening despite medical therapy, and you are unsure whether the next step should be mavacamten, ablation, or surgery.
- You have been told your risk of sudden death warrants an ICD, but you want a second set of eyes on the data.
- Your echocardiographic findings are borderline — for example, a resting gradient of 25-40 mmHg — and you are uncertain whether intervention is warranted.
- You are an athlete or physically active person who has been given blanket restrictions without individualized risk assessment.
HCM is a condition where nuance matters enormously, and where the difference between the right and wrong decision can shape years of your life. An independent review by a fellowship-trained cardiac surgery team — one with no financial stake in performing your procedure — can be the most valuable investment you make in your health.
If you are living with hypertrophic cardiomyopathy and facing decisions about medication changes, septal reduction therapy, ICD placement, or lifestyle restrictions, a WhiteGloveMD second opinion can help. Our team reviews your imaging, your records, and your clinical picture to give you clear, unbiased guidance. Start your review today.